TSRO Share Price

Open 114.43 Change Price %
High 117.65 1 Day 1.03 0.90
Low 114.29 1 Week 0.00 0.00
Close 115.77 1 Month -7.23 -5.88
Volume 286672 1 Year -28.48 -19.74
52 Week High 192.94
52 Week Low 106.64
TSRO Important Levels
Resistance 2 118.88
Resistance 1 117.60
Pivot 115.90
Support 1 113.94
Support 2 112.66
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
MU 44.31 6.39%
MU 44.31 6.39%
MU 44.31 6.39%
RIMM 13.03 0.39%
More..
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
SCHS 0.04 33.33%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
HLIT 3.70 25.42%
OTT 2.39 25.13%
QNST 8.90 20.76%
VRTA 4.00 19.40%
SNSS 2.56 19.07%
GCFB 0.44 18.92%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
GMETP 0.15 -76.92%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

TESARO, Inc. (NASDAQ: TSRO)

TSRO Technical Analysis 4
As on 31st Oct 2017 TSRO Share Price closed @ 115.77 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 140.36 & Sell for SHORT-TERM with Stoploss of 119.87 we also expect STOCK to react on Following IMPORTANT LEVELS.
TSRO Target for November
1st Target up-side 127.27
2nd Target up-side 135.33
3rd Target up-side 143.39
1st Target down-side 104.27
2nd Target down-side 96.21
3rd Target down-side 88.15
TSRO Other Details
Segment EQ
Market Capital 430751968.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.tesarobio.com
TSRO Address
TSRO
1000 Winter Street
Suite 3300
Waltham, MA 02451
United States
Phone: 339-970-0900
TSRO Latest News
Interactive Technical Analysis Chart TESARO, Inc. ( TSRO NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on TESARO, Inc.
TSRO Business Profile
TESARO, Inc. (TESARO) is a development-stage, oncology-focused biopharmaceutical company for cancer patients. The Company focuses on rolapitant and TSR-011 product. The Company�s marketed products and product candidates in development treat cancer through non-specific damage to cellular components or alter cell metabolism or internal repair mechanisms to the demise of cancer cells. Rolapitant is a potent and long-acting neurokinin-1, or NK-1, receptor antagonist is in Phase III clinical trials for the prevention of chemotherapy induced nausea and vomiting (CINV). TSR-011 is an orally available anaplastic lymphoma kinase (ALK), inhibitor (targeted anti-cancer agent) is in preclinical development.